Table 4.
Geometric mean (95% confidence interval) serum lipid and other biomarkers at baseline and on average during 2 months of intervention by treatment group
| Placebo | 400 mg EGCG as PPE | 800 mg EGCG as PPE | P1 | P2 | P3 | |
|---|---|---|---|---|---|---|
| Cholesterol (mg/dl) | ||||||
| Baseline | 216 (203,231) | 218 (205,231) | 208 (195,221) | 0.54 | ||
| Ave month 1–2 | 216 (203,229) | 207 (196,219) | 202 (190,214) | |||
| Change % | −0.2% | −5.0% | −3.1% | |||
| P value | 0.90 | 0.01 | 0.045 | 0.072 | 0.44 | |
| Cholesterol LDL (mg/dL) | ||||||
| Baseline | 127 (114,142) | 129 (117,143) | 122 (110,136) | 0.74 | ||
| Ave month 1–2 | 128 (116,141) | 119 (109,130) | 114 (104,126) | |||
| Change % | 0.5% | −7.9% | −6.6% | |||
| P value | 0.86 | 0.007 | 0.012 | 0.021 | 0.73 | |
| Cholesterol HDL (mg/dL) | ||||||
| Baseline | 61 (56,67) | 62 (57,67) | 59 (54,63) | 0.59 | ||
| Ave month 1–2 | 61 (56,67) | 62 (57,67) | 58 (53,63) | |||
| Change % | −0.3% | 0.0% | −1.2% | |||
| P value | 0.87 | 0.98 | 0.56 | 0.89 | 0.61 | |
| Triglycerides (mg/dL) | ||||||
| Baseline | 106 (91,124) | 107 (93,123) | 108 (93,125) | 0.99 | ||
| Ave month 1–2 | 109 (94,127) | 106 (93,121) | 118 (103,136) | |||
| Change % | 3.2% | −1.1% | 9.8% | |||
| P value | 0.57 | 0.79 | 0.042 | 0.92 | 0.090 | |
| Glucose (mg/dL) | ||||||
| Baseline | 97 (91,103) | 99 (94,105) | 103 (97,110) | 0.32 | ||
| Ave month 1–2 | 99 (94,105) | 98 (93,103) | 101 (95,106) | |||
| Change % | 2.7% | −1.3% | −2.6% | |||
| P value | 0.052 | 0.13 | 0.15 | 0.008 | 0.50 | |
| Insulin (uIU/mL) | ||||||
| Baseline | 7.3 (5.7, 9.5) | 8.5 (6.6,10.9) | 9.5 (7.4,12.3) | 0.39 | ||
| Ave month 1–2 | 8.9 (6.9,11.5) | 8.3 (6.5,10.5) | 9.0 (7.0,11.5) | |||
| Change % | 19.7% | −2.6% | −5.8% | |||
| P value | 0.059 | 0.65 | 0.33 | 0.010 | 0.69 | |
| Glycosylated Hemoglobin (%) (HbA1c) | ||||||
| Baseline | 5.9 (5.7,6.2) | 5.9 (5.6,6.2) | 6.3 (6.0,6.5) | 0.071 | ||
| Ave month 1–2 | 5.9 (5.6,6.2) | 5.8 (5.5,6.0) | 6.2 (5.9,6.5) | |||
| Change % | −0.3% | −1.5% | −1.1% | |||
| P value | 0.71 | 0.044 | 0.10 | 0.26 | 0.71 | |
| IGF-1 (ng/ml) | ||||||
| Baseline | 110 (97,124) | 109 (97,122) | 95 (84,107) | 0.15 | ||
| Ave month 1–2 | 110 (98,124) | 109 (98,122) | 94 (83,106) | |||
| Change % | 0.3% | 0.1% | −0.8% | |||
| IGFBP-3 (μg/ml) | ||||||
| Baseline | 3.9 (3.5,4.2) | 4.0 (3.7,4.4) | 3.7 (3.4,4.0) | 0.37 | ||
| Ave month 1–2 | 3.9 (3.6,4.2) | 3.9 (3.6,4.3) | 3.6 (3.3,3.9) | |||
| Change % | 0.4% | −2.01% | −2.8% | |||
| P value | 0.76 | 0.068 | 0.053 | 0.078 | 0.66 | |
| Adiponectin (μg/ml) | ||||||
| Baseline | 17.1 (14.4,20.1) | 16.4 (14.1,19.1) | 17.0 (14.5,20.0) | 0.93 | ||
| Ave month 1–2 | 18.0 (15.2,21.3) | 16.3 (14.0,19.0) | 16.7 (14.1,19.6) | |||
| Change % | 5.4% | −0.6% | −2.2% | |||
| P value | 0.27 | 0.90 | 0.58 | 0.084 | 0.78 | |
1
P value for difference between the 3 groups at baseline (ANOVA for continuous variable, 2 df)
2
P value for difference in change between the placebo versus the two PPE groups
3
P value for difference in change between the 400 mg and 800 mg PPE groups